All In Biotech

Drug Trial Radar · NCT05320198

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 6, 2022

Primary completion

May 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

Conditions

  • Myelofibrosis; Anemia
  • Anemia
  • Myelofibrosis
  • Myelofibrosis Due to and Following Polycythemia Vera
  • Primary Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Myelodysplastic Syndromes

Interventions

  • DISC-0974Drug

    DISC-0974 is administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  2. Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  3. Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  4. Safety and Tolerability of DISC-0974 (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  5. Safety and Tolerability of DISC-0974 assessed through blood testing (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  6. Safety and Tolerability of DISC-0974 assessed through urine testing (Phase 1b only)Time frame: From Day 1 to the end of treatment on Day 169
  7. Transfusion-dependent (TD) high cohort: transfusion independence (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169
  8. TD low cohort: transfusion independence (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169
  9. Non-transfusion-dependent (nTD) cohort: anemia response (Phase 2 only)Time frame: From Day 1 to the end of treatment on Day 169

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona · Recruiting

  • City of Hope - Duarte

    Duarte, California · Recruiting

  • City of Hope - Lennar

    Irvine, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Sylvester Cancer Center - U Miami

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Northwest Oncology

    Rolling Meadows, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Washington University St.Louis

    St Louis, Missouri · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Montefiore

    New York, New York · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Terminated

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Sargon Research - Pennsylvania Cancer Specialists and Research Center

    Gettysburg, Pennsylvania · Withdrawn

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • Baylor Scott & White

    Temple, Texas · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Linear Clinical Research

    Nedlands, Australia · Recruiting

  • Western Health

    Saint Albans, Australia · Recruiting

  • St. Vincent's Hospital

    Sydney, Australia · Recruiting

  • Perth Blood Institute

    West Perth, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.